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Palladin Is a Neuron-Specific Translational Target of mTOR
Signaling That Regulates AxonMorphogenesis
Yusuke Umegaki,1,2 Antonio Martı´nez Brotons,1,2 Yui Nakanishi,1,2 Zhongyue Luo,1,2 Hanlu Zhang,1,2 XAzad Bonni,3
and XYoshiho Ikeuchi1,2
1Institute of Industrial Science, and 2Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, Tokyo
153-8505, Japan, and 3Department of Neuroscience, Washington University School of Medicine, St. Louis, Missouri 63110
The mTOR signaling pathway regulates protein synthesis and diverse aspects of neuronal morphology that are important for brain
development and function. To identify proteins controlled translationally bymTORsignaling,we performed ribosomeprofiling analyses
in mouse cortical neurons and embryonic stem cells upon acute mTOR inhibition. Among proteins whose translation was significantly
affected bymTOR inhibition selectively in neurons, we identified the cytoskeletal regulator protein palladin, which is localizedwithin the
cell body and axons in hippocampal neurons. Knockdown of palladin eliminated supernumerary axons induced by suppression of the
tuberous sclerosis complex protein TSC1 in neurons, demonstrating that palladin regulates neuronal morphogenesis downstream of
mTOR signaling. Our findings provide novel insights into an mTOR-dependent mechanism that controls neuronal morphogenesis
through translational regulation.
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Introduction
Neuronal morphogenesis during development is critical for nor-
mal brain circuitry and function, and disruption of neuronal
morphogenesis may lead to diverse brain disorders (Hu et al.,
2014). Accumulating evidence suggests that precise regulation of
protein synthesis is essential in the control of neuronal morpho-
genesis (Brittis et al., 2002; Bramham and Wells, 2007; Deglin-
certi and Jaffrey, 2012; Jung et al., 2012). The mTOR signaling
pathway is a fundamental regulator of protein synthesis, and con-
trols diverse aspects of neuronal morphology (Tavazoie et al.,
2005; Costa-Mattioli and Monteggia, 2013; Takei and Nawa,
2014). The mTOR kinase protein complex mTORC1 promotes
protein synthesis by phosphorylation of translation regulators,
including S6K and 4EBP. TSC1 and TSC2 are critical negative
regulators of mTOR kinase activity, andmutations of these genes
cause the genetic disorder tuberous sclerosis complex (TSC). TSC
features benign tumors, hypopigmented skin patches, and neu-
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Significance Statement
This study reports the discovery of neuron-specific protein translational responses to alterations of mTOR activity. By using
ribosome profiling analysis, which can reveal the location and quantity of translating ribosomes on mRNAs, multiple aspects of
protein translation were quantitatively analyzed in mouse embryonic stem cells and cortical neurons upon acute mTOR inhibi-
tion. Neurons displayed distinct patterns of ribosome occupancy for each codon and ribosome stalling during translation at
specific positions of mRNAs. Importantly, the cytoskeletal regulator palladin was identified as a translational target protein of
mTOR signaling in neurons. Palladin operates downstream of mTOR to modulate axon morphogenesis. This study identifies a
novel mechanism of neuronal morphogenesis regulated by mTOR signaling through control of translation of the key protein
palladin.
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rological disorders including epilepsy, intellectual disability, and
autism spectrumdisorders (ASDs).Mutations of TSC1 andTSC2
lead to hyperactivation of mTOR kinase and consequent disrup-
tion of neuronal morphogenesis (Tavazoie et al., 2005).
The mTOR signaling pathway modulates protein synthesis
activity globally (Costa-Mattioli and Monteggia, 2013; Faller et
al., 2015). However, recent studies have suggested that mTOR
signalingmay also regulate production of specific proteins. Upon
stimulation, mTOR signaling rapidly induces translation of
mRNAs encoding components of the protein synthesis machin-
ery, therefore promoting general protein translation activity in
the cell. Many of the proteins whose translation is augmented in
response to mTOR activation are produced from mRNAs con-
taining an oligo-pyrimidinemotif at their 5 end (5TOP), which
modulates initiation of translation depending on mTOR activity
(Jefferies et al., 1994). This mechanism contributes to cell-type-
specific functions through translational control of specific
mRNAs bearing 5TOP-likemotifs (Hsieh et al., 2012; Thoreen et
al., 2012; Olshen et al., 2013). In addition to promoting initiation
of translation,mTOR regulates elongation of translation through
modulation of elongation factors (Browne and Proud, 2004;
Kenney et al., 2014). Recent studies have revealed that translation
elongation factorsmaymodulate production of specific proteins,
with specific consequences in neurons (Park et al., 2008; Verpelli
et al., 2010; Shepherd and Bear, 2011; Kenney et al., 2014). We
thus hypothesized that the mTOR signaling pathway might con-
trol neuronal morphology by regulating production of specific
proteins in neurons.
In this study,wehavediscovered thatmTORsignaling selectively
regulates translation of distinct proteins in neurons including the
cytoskeletal regulator palladin, which mediates mTOR-regula-
tion of axonmorphogenesis. Our findings provide insights into a
translational mechanism that regulates neuronal morphology
downstream of the mTOR signaling pathway.
Materials andMethods
Ribosome profiling. Ribosome profiling was performed as described pre-
viously (Ingolia et al., 2012). Cortical neurons were prepared from E16
CD-1 (ICR, RRID:IMSR_CRL:22) mouse embryos (either sex), and cul-
tured for 8 d in vitro and treated with the mTOR inhibitor Torin 1 (100
nM; Tocris Bioscience) or vehicle for 2.5 h, which allows to capture direct
changes in mTOR-dependent protein synthesis before secondary feed-
back effects (Hsieh et al., 2012). EB3 mouse embryonic stem (ES) cells
(RRID: CVCL_J647) were provided by RIKEN BRC (Niwa et al., 2002;
Ogawa et al., 2004), andmaintained in 2i-LIF medium. Subconfluent ES
cells were treated with the mTOR inhibitor Torin 1 (100 nM) or vehicle
for 2.5 h. After treatment with Torin 1 or vehicle (DMSO), cells were
lysed in a buffer containing cycloheximide, and the polysome was pro-
cessed for ribosome profiling analysis as described previously (Ingolia et
al., 2012). Ribosome-mRNA complex was stabilized with cycloheximide
upon lysis of cells, and followed by treatment with RNase I. The undi-
gested ribosome-protected mRNA fragments were then subjected to se-
quencing library preparation. Next-generation sequencing analysis and
subsequent computational analysis revealed codon-level ribosome dis-
tribution on mRNAs. For mRNA-seq, mRNAs were extracted from cells
prepared in parallel and subjected to next generation sequencing library
preparation. The libraries were sequenced with HiSeq2500 (Illumina) as
single-end reads of 50 bp.
Data processing of ribosome profiling. The short reads of the ribosome
profiling and mRNA-seq were processed as follows. Adaptor sequence
(CTGTAGGCACCATCAAT) was trimmed from the reads using BBDuk
from the BBTools suite (U.S. Department of Energy Joint Genome Insti-
tute) with the following parameters: ktrim r, k 17, hdist 1,mink
10 minlength  25, maxlength  40. To remove reads derived from
noncoding RNAs, the trimmed reads were aligned to mouse rRNA,
tRNA, snRNA, snoRNA, and lncRNA sequences downloaded from
RNAcentral database (The RNAcentral Consortium, 2017) using Bowtie
1.1.2 (Langmead et al., 2009; RRID:SCR_005476), and the aligned reads
were discarded. Then, the remaining reads were aligned to the mouse
genome (GRCm38.p5) using STAR (Dobin et al., 2013; RRID:
SCR_015899). We allowed a maximum of two mismatches, and dis-
carded unannotated and noncanonical splice junction reads with
following parameters: outFilterMismatchNmax 2; outFilterIntronMotifs
RemoveNoncanonicalUnannotated. The genomic annotation file con-
taining splice junction information was obtained from GENCODE
(release M12; Mudge and Harrow, 2015; RRID:SCR_014966). For tran-
script level ribosome occupancy analysis, we calculated changes of trans-
lation efficiency of each gene by comparing read counts of ribosome
profiling and mRNA-seq. We performed three independent biological
repeats and statistical analyses using Babel R package as reported (Olshen
et al., 2013; RRID:SCR_004307). Previous study reported that acute
mTOR inhibition moderately suppress translation of nearly all mRNAs
(Thoreen et al., 2012). This effect is normalized by Babel package
and only the mRNAs significantly affected by Torin 1 treatment were
identified.
To assess precise positions of ribosome occupancy on mRNAs,
uniquely aligning reads with length between 25 and 35 nt were used. The
unique reads were mapped to CDS coordinates usingmapToTranscripts
function from GenomicFeatures R package (Lawrence et al., 2013). The
reads were assigned to the positions corresponding to the first nucleotide
of the P-site, by shifting the 5 end of each read by12 (for reads 25–30
nt long),13 (31–34 nt) or14 (35 nt) positions. The offsets for reads
with various length were determined by Plastid (Dunn and Weissman,
2016). For this step, only the representative isoform for each gene regis-
tered in UCSC Table Browser knownCanonical track (Karolchik et al.,
2004; RRID:SCR_005780) was used. Bioinformatic analysis of ribosome
occupancy data was performed using custom R scripts that are available
upon request.
For pause identification, a “pausing score” for each codon was calcu-
lated by dividing the ribosome occupancy in each codon by the average
occupancy of codons across coding sequences (CDSs) of the same tran-
script. Codonswith a pausing score10were considered to be ribosomal
pausing sites. Venn diagrams for genes containing at least one pause were
generated using VennDiagram R package (Chen and Boutros, 2011;
RRID:SCR_002414). The first 15 and last 5 nt of each CDSwere excluded
due to accumulation of ribosomes at initiation and termination sites.
Long stretches of codonswithout aligned reads are presumably caused by
non-uniqueness of the sequence, which reduces average occupancy on
codons excessively. To avoid false-positive detections of ribosome paus-
ing due to this confound, a continuous stretch of codons to which no
reads were mapped was collapsed to one codon. For these analyses, only
well expressed genes (CDS with a median of2 reads per 5 codon win-
dow) were considered as described previously (Ingolia et al., 2012).
For codon-specific ribosome occupancy analysis, we first calculated
the number of reads containing each of the 61 aa-coding codons at po-
sitions corresponding to A-, P-, and E-sites of ribosomes. Codon-specific
ribosome occupancy was normalized by the average occupancy of three
3 side codons adjacent to the A-site, as reported (Nedialkova and Leidel,
2015). Codons in those positions have not been translated yet but are
already inside themRNAchannel; therefore, they are not expected to bias
codon frequencies. Codon-specific ribosome occupancy was then con-
verted to percentage of total coding sequence reads in each sample, and
the relative occupancy change was calculated respect to untreated corti-
cal neuron. For this analysis, only in-frame reads from transcripts with at
least 64 ribosome footprints mapped to them were included. The first
and last 50 codons from each representative CDSwere excluded from the
analysis to avoid the potential bias at the beginning and end of genes.
5TOP analysis.Genome-wide analysis of 5TOPwas performed using
R scripts, available upon request. To determine ratio of mRNAs bearing
5TOP-like motif in all mRNAs transcribed from each gene, we assessed
the 5-end sequence of mRNAs and their abundance using the
FANTOM5 quantitative transcription start site dataset (Lizio et al., 2015;
RRID:SCR_002678). The transcription start site [CAGE tag starting site
(CTSS)] datasets for neuronal differentiation of mouse ES cells was
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downloaded from the FANTOM5 database. For this analysis, mm9
mouse reference assembly was used for consistency with FANTOM5
data. Positions with 2 reads were filtered out from CTSS datasets to
reduce noise. CTSSs with at least four pyrimidines in the 5end 5 nt were
identified as producing 5TOP-like motif-containing mRNAs. For each
dataset, total CTSS and 5TOP-preceding CTSSweremappedwithin 500
bp to both directions of transcription start sites of canonical transcripts
using GenomicAlignments’ summarizeOverlaps function (Lawrence et
al., 2013). The 5TOP ratio was calculated as the division of 5TOP-
preceding CTSS count and total CTSS count for each gene and each
dataset.
Antibodies. For immunostaining, the following antibodies were used:
anti- III Tubulin (Tuj1; Covance, MMS-435P; RRID:AB_2313773),
anti-Tau1 (Millipore, MAB3420; RRID:AB_94855), anti-palladin (Santa
CruzBiotechnology, sc-68900; RRID:AB_2158884; andProteintech, 10853-
1-AP; RRID:AB_2158782), and anti-GFP (rabbit antiserum generated
against full-length eGFP, andNeuroMab, 75-132; RRID:AB_10672529).
For immunoblotting, we used following antibodies: anti-palladin
(Proteintech, 10853-1-AP; RRID:AB_2158782), anti-TSC1 (Cell Signal-
ing Technology, 4906; RRID:AB_2209790 and Life Technology, 37-0400;
RRID:AB_2533292), anti-S6 (Cell Signaling Technology, 2217; RRID:
AB_331355), anti-phospho S6 (Cell Signaling Technology, Ser 240/244,
5364; RRID:AB_10694233), anti-Zfp36 (Santa Cruz Biotechnology, SC-
374305; RRID:AB_10988939), anti-nucleoporin p62 (BD Biosciences,
610497; RRID:AB_397863), anti-Flag (Sigma-Aldrich, M2; RRID:
AB_262044), anti-puromycin (Kerafast, 3RH11; RRID:AB_2620162),
and anti-ERK (Cell Signaling Technology, 9102; RRID:AB_330744).
Genome editing. The TSC1 gene was genetically manipulated using the
CRISPR/Cas9 system (Ran et al., 2013). According to the inventors’ di-
rection, pSpCas9(BB)-2A-Puro (pX459) V2.0 was modified to target the
TSC1 gene by inserting the annealed oligonucleotides 5-CACCGCAA
CATGCCCCAGCAGCGAG-3 and 5-AAACCTCGCTGCTGGGGCA
TGTTGC-3. After transfecting Neuro2A cells (RRID:CVCL_0470) with
theCRISPRplasmid or control plasmidwith FuGENEHD (Promega). as
per the manufacturer’s protocol, cells were replated and treated with
puromycin. Cells were sparsely plated in 150mmdish, and colonies were
manually picked. The mutated genomic region was amplified with PCR
using the primers 5-TTCATGGGGTGAGCATATCTCCAG-3 and 5-
CCCACATGGTCGAAAGGAAGAACT-3. The mutation was first de-
tected by T7 endonuclease 1 (New England BioLabs), and then the
PCR product of the edited region was cloned into a plasmid by TA
cloning (pCR2.1-TOPO, Life Technologies) to reveal the mutations
by sequencing.
RNAi. For knockdown of palladin, we have generated plasmids ex-
pressing short RNA hairpin targeting two distinct regions of palladin






GCTCTTCTGGGCTCTTTC-3 were cloned into U6 RNAi plasmid to
generate palladin RNAi 1 and 2, respectively, as described previously
(Gaudilliere et al., 2002). The TSC1 RNAi plasmid has been described
previously (Mejia et al., 2013).
Immunoblotting analysis of isolated neurites. Neurites were isolated as
described before with modifications (Vidaki et al., 2017). Hippocampal
neurons from E16 mice were plated on the top component of a hanging
insert with 1 m membrane pores (Merck, Millipore). The membrane
was coated on both sides with poly-L-lysine. The cells were cultured for
5 d. To analyze proteins in the neurites, cell bodies were scraped from the
top component of the filter, leaving the neurites at the bottom. After
scraping the cells, Torin 1 was added to the neurites and incubated for
12 h, which allows us to evaluate changes of palladin protein abundance
before neurites degenerate. Lysates of the neurites or whole cells were
analyzed by immunoblotting and intensity of the bands was quantified.
Morphological analysis.Hippocampal neurons fromE16 or E17mouse
embryos were plated on coverslips coated with poly-L-lysine (Sigma-
Aldrich) and cultured in Neurobasal media (ThermoFisher) supple-
mented with B27, glutamine, and penicillin/streptomycin. For axonal
morphology analysis, hippocampal neurons were transfected 2–6 h after
plating using a calcium phosphate method modified from a method
described previously (Konishi et al., 2004) with RNAi or expression plas-
mids together with GFP expression plasmid to visualize transfected neu-
rons. To count number of axons per cell, we identified axons with Tau1
immunostaining.
Experimental design and statistical analysis. All ribosome profiling was
completed with samples of three independent experiments. All morpho-
logical analyses were completed from a minimum of three independent
experiments. Statistical analyses were performed with R (RRID:
SCR_001905). All histograms for morphological analyses are presented
as mean  SEM unless otherwise noted. Student’s t test was used for
comparisons in experiments with two sample groups. In experiments
with more than two sample groups, ANOVAwas performed followed by
Bonferroni’s post hoc test for pairwise comparison among three and
greater than three groups.
Results
Ribosome profiling analyses suggest palladin is a
translational target of mTOR signaling
“Ribosome profiling” analysis can reveal quantitative distribu-
tion patterns of translating ribosomes onmRNAs in cells (Ingolia
et al., 2012). We used this method to analyze neuron-specific
effects of acute mTOR inhibition on the distribution of translat-
ing ribosomes on mRNAs (Fig. 1A). By comparing the effect of
acute Torin 1 treatment of neurons and ES cells in ribosome
profiling, we aimed to uncover cell-type-specific translational re-
sponses to alteration of mTOR activity (Fig. 1B,C). To identify
neuron-specific translational targets of the mTOR signaling
pathway, we searched for changes of ribosome distribution pat-
terns upon acute treatment ofmouse cortical neurons with Torin
1, and compared these changes with those in mouse ES cells.
Because the mTOR signaling pathway controls initiation and
elongation of translation, we analyzed both steps by interrogating
three different aspects of translation. For translation elongation,
we investigated codon-specific ribosome occupancy and ribo-
some stalling, which are two distinct aspects of translation asso-
ciated with elongation. For translation initiation, we analyzed
translation efficiency, which is determined by integrating ribo-
some occupancy throughout open reading frames (ORFs) and
normalized by abundance of the corresponding mRNA.
First, we evaluated codon-specific ribosome occupancy on the
61 codons, through which we can examine relative translation
elongation speed of each codon. The frequency of each codon
appeared at the positions corresponding to the three tRNA ac-
cepting A-, P-, and E-sites of the ribosome was calculated for all
footprints mapped to highly expressed transcripts, and normal-
ized by overall expression and length ofORFs (Fig. 2A).Whenwe
compared the datasets in neurons, we observed onlyminor Torin
1-induced changes on ribosome occupancy for codons at A-, P-,
and E-sites of the ribosome. An identical analysis in ES cells sim-
ilarly showed little Torin 1-induced changes in codon-specific
ribosome occupancy. These data suggest that mTOR does not
globally alter the elongation rate for a particular codon during
translation. Interestingly, ribosome occupancy for some codons
appeared to be different between neurons and ES cells. For exam-
ple, ribosome occupancy for histidine codons at A-site was in-
creased in ES cells compared with neurons (Fig. 2A), suggesting
that translation rate of histidine codons might be reduced in ES
cells due to limitedHis-tRNAavailability. Proline codons showed
increased ribosomeoccupancy at P-site in ES cells comparedwith
neurons (Fig. 2A), suggesting that peptidyl transfer on Pro-
tRNAPro might be slower in ES cells than in neurons.
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Figure 1. Ribosome-profiling analysis of neurons and ES cells uponmTOR inhibition.A, Schematics of ribosome profiling in this study.B, Torin 1 is an inhibitor ofmTOR kinase, which inactivates
translationmachinery through downstream substrates. C, Lysates from neurons and ES cells treatedwith 100 nM Torin 1 or vehicle (control) for 2.5 hwere immunoblottedwith the phospho-S6 and
S6 antibodies. Phosphorylation of S6 was significantly suppressed by the acute treatment with Torin 1. The phospho-S6 intensity was quantified and normalized by S6. The average relative
abundance of three replicates was indicated.
Figure 2. Differences in ribosome occupancy distribution between ES cells and neurons. A, Mean change in codon-specific ribosome occupancy in untreated neurons, Torin 1-treated neurons,
untreated ES cells, and Torin1-treated ES cells, for ribosomal A-site (top), P-site (middle), and E-site (bottom). Error bars represent SD (n3).B,C, Venndiagrams showing thenumber of genes that
present a translational pause in the CDS body when comparing untreated and Torin 1-treated cortical neurons (B) or untreated cortical neurons and ES cells (C). The percentage of genes in each
category respect to the combinednumber of pause-presenting genes is given in parentheses.D, E, Comparison of ribosome footprint profile over the CDS of Hsp90ab1 (D) andGab1 (E) in ES cells and
cortical neurons.
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Because ribosome stalling may impact
protein expression, localization and fold-
ing (Darnell and Klann, 2013; Wilson et
al., 2016), we next investigated ribosome
stalling events during translational elon-
gation. We detected 784 and 480 genes
with ribosome stalling events in neurons
cultured without and with Torin 1, re-
spectively (Fig. 2B). Ribosome stallingwas
observed in both conditions for a substan-
tial fraction of genes (368 genes). Stalling
in 416 and 112 genes was detected selec-
tively in control neurons and Torin
1-treated neurons, respectively. However,
uponmanual review, stalling peaks exhib-
iting read numbers substantially altered
by Torin 1-treatment were not evident.
We also compared genes exhibiting ribo-
some stalling between neurons and ES
cells (Fig. 2C). These analyses revealed
fewer overlapping genes exhibiting ribo-
some stalling in both cell types than Torin
1-treated and untreated neurons. Inter-
estingly, some mRNA loci showed a sig-
nificant difference in pausing intensity
despite similar levels of expression in the
two cell types. For example, the Hsp90ab1
gene displayed higher pausing intensity at
a specific site selectively in ES cells (Fig.
2D), whereas a stalling site in the Gab1
gene was neuron-specific (Fig. 2E). To-
gether, these results suggest that mTOR
regulation plays a minor role in the con-
trol of ribosome stalling on mRNAs, and
developmental changes may have a larger
impact on ribosome stalling.
Finally, we searched for Torin 1-indu-
ced changes on translational efficiency of
transcripts, defined as the ratio of ribo-
some occupancy relative to transcript
abundance. These analyses revealed mod-
ulation of protein translation upon acute
mTOR inhibition specifically in neurons
(Fig. 3). We found that ribosome occu-
pancy of 561 and 54 mRNAs was signifi-
cantly downregulated and upregulated,
respectively, upon Torin 1-treatment in
neurons (Fig. 3A). In ES cells, ribosome
occupancy of 2338 and 31 mRNAs was
significantly downregulated and upregu-
Figure 3. Differences in translation efficiency of ORFs between ES cells and neurons. A,B, Scatter plots of translation efficiency
of highly expressed genes in neurons (A) and ES cells (B). Significantly downregulated or upregulated genes are highlighted in
colors. C, Venn diagram illustrating overlap of genes whose translational efficiency was significantly downregulated by Torin
1-treatment in neurons and ES cells.D, Venn diagram illustrating overlap of geneswhose translational efficiencywas significantly
downregulated by Torin 1-treatment in this report (neurons and ES cells) and a previous study (MEFs; Thoreen et al., 2012).
4
E, Categories of gene ontology significantly enriched in the
genes that are affected by Torin 1 specifically in neurons, in
both neurons and ES cells, and specifically in ES cells. F, Sche-
matic of alternative transcription start sites producing mRNAs
with and without 5TOP sequences at a different ratio in dif-
ferent cell types.G, A scatter plot of ratio ofmRNAs containing
5TOP in neurons and ES cells. H, Venn diagram of genes that
are mTOR-regulated selectively in neurons and genes that
generate mRNAs containing 5TOP to a greater extent in neu-
rons than ES cells. The overlapping 10 genes are listed with
p values.
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lated, respectively, upon Torin 1 treatment (Fig. 3B). One hun-
dred and thirty mRNAs were commonly downregulated in both
cell types, whereas no overlap between upregulated mRNAs be-
tween the datasets were observed. Four hundred and thirty-one
mRNAs were only downregulated in neurons, and 2208 mRNAs
were only downregulated in ES cells. We compared our result
with a previously performed ribosome profiling analysis with
mouse embryonic fibroblasts (MEFs) upon inhibition of mTOR
signaling (Thoreen et al., 2012; Fig. 3D). Among the reported 253
genes translationally downregulated by Torin 1 treatment in
MEFs, 66% (167 genes) overlapped with the genes downregu-
lated in ES cells (Fig. 3D).On the other hand, only 20% (50 genes)
of those downregulated in MEFs upon Torin 1 treatment over-
lappedwith the genes downregulated in neurons. Together, these
data demonstrate that neurons respond differentially to the acute
inhibition of mTOR signaling.
Gene ontology (GO) enrichment analysis was performed to
detect enrichment of cellular functions of the translationally
downregulated genes in our ribosome profiling analyses (Fig.
3E). Genes encoding translation machinery proteins were en-
riched among those affected by Torin 1 commonly in neurons
and ES cells. Consistent with our results, previous studies have
demonstrated components of the translational machinery are
common targets ofmTOR signaling (Hsieh et al., 2012; Gentilella
et al., 2015). Among the genes affected by Torin 1 specifically in
ES cells, genes related to energy metabolism and mitochondrial
function were enriched (Fig. 3E). Interestingly, genes encoding
cytoskeletal regulators related to “focal adhesion” and “stress
fiber” were enriched among those genes affected by Torin
1-treatment only in neurons (Fig. 3E), suggesting that transla-
tional targets of the mTOR signaling pathway might directly reg-
ulate neuronal morphology through control of cytoskeletal
structures.
Alternative transcriptional start sites (TSS) often produce
mRNAs bearing different 5-terminal sequences, and thus selec-
tion of TSS may determine whether mRNAs contain 5 terminal
oligo-pyrimidine tract (5TOP) sequences (Thoreen et al., 2012).
To identify candidate proteins translationally regulated by
mTOR specifically in neurons with a method distinct from ribo-
some profiling analysis, we performed a global in silico search for
genes switching TSSs to produce mRNAs with 5TOP sequences
more during neural development. We used the FANTOM5
CAGE peaks time course dataset for neural differentiation of
mouse ES cells (Forrest et al., 2014; Lizio et al., 2015). Analysis of
the 5-terminal sequences of mRNAs produced from TSS used in
differentiated neurons and ES cells suggested that a subset of
genes produce substantially more 5TOP-containing mRNAs in
the differentiated neurons than in the ES cells by switching alter-
native TSS during neuronal development (Fig. 3F). We found
178 genes using TSSs producing mRNAs containing the 5TOP
motif in higher proportion in differentiated neurons than ES cells
(Fig. 3G). By intersecting these results with our ribosome profil-
ing results, we found only 10 genes both represent translational
targets of mTOR signaling and produce 5TOP-containing
mRNAs selectively in neurons (Fig. 3H). Among them, palladin
was subjected to further analysis, since it was classified as a cyto-
skeletal regulator in the GO term enrichment analysis. In previ-
ous reports, palladin was not detected as a translational target of
mTOR signaling in other cells (Hsieh et al., 2012; Thoreen et al.,
2012; Livingstone et al., 2015; Park et al., 2017), supporting that
production of palladin is specifically controlled bymTOR signal-
ing in neurons.
Palladin is translationally regulated by mTOR and localized
in axons
The ribosome profiling analysis suggested that translation effi-
ciency of palladin is impaired uponmTOR inhibition in neurons.
To examine whether mTOR activity influences the levels of pal-
ladin protein, we assessed the effect of inhibition of mTOR activ-
ity on palladin expression in neurons. The neurons were treated
with Torin 1 over 24 h before lysis, which allows the palladin
protein levels to reflect cumulative effects of translation efficiency
alterations. The levels of palladin protein were reduced in neu-
rons upon exposure to Torin 1 (Fig. 4A), suggesting that palladin
translation is controlled bymTORactivity. The palladin antibody
was validated by endogenous knockdown of palladin using two
distinct short hairpin RNAs (shRNAs; Fig. 4B). The RNAi effect
was also confirmed by knockdown of exogenously expressed pal-
ladin inHEK293T cells (Fig. 4B). To checkwhether Torin 1 treat-
ment reduces the levels of another protein that was affected by
Torin 1 specifically in neurons in the ribosome profiling analyses,
we performed immunoblotting analysis of Zfp36 in neurons.
Consistent with our ribosome profiling result, the protein levels
of Zfp36 were reduced in cortical neurons upon Torin 1 treat-
ment (Fig. 4C). In other experiments, we assessed the effect of
additional mTOR inhibitors in addition to Torin 1 on the levels
of palladin in cortical neurons. We found that the mTOR inhib-
itors Torin 2 and PP242 reduced the levels of palladin protein
(Fig. 4D), further supporting the conclusion that inhibition of
mTOR reduces the translation of palladin in cortical neurons.
Torin 1 inhibits the two distinct mTOR-containing protein
complexes mTORC1 and mTORC2 (Thoreen et al., 2009). Al-
though mTORC1 directly controls protein synthesis, mTORC2
controls other cellular activities including actin cytoskeleton. To
reveal overall activity of protein synthesis within neurons, we
performed SUnSET analysis (Schmidt et al., 2009) upon treat-
ment with Torin 1 or actin polymerization inhibitor cytochalasin
D. We found that Torin 1, but not cytochalasin D, reduced the
amount of newly synthesized proteins (Fig. 4E), suggesting that
actin polymerization had little or no effect on protein synthesis.
In other analyses, we found that cytochalasin D did not reduce
palladin protein levels in cortical neurons (Fig. 4F). These data
suggest that the effect of Torin 1 treatment on palladin protein
translationwas not caused by actin regulation throughmTORC2,
and hence presumably via regulation of protein synthesis
through mTORC1.
We nextmutated the gene encoding themTOR inhibitor pro-
tein TSC1 using the CRISPR/Cas9 system (Ran et al., 2013) in
neural cells. We tested the effect of mTOR activation upon mu-
tation of TSC1 on the levels of palladin in cells. We confirmed
thatmutation of the TSC1 gene downregulated the levels of TSC1
protein and increased phosphorylation of the mTOR down-
stream signaling protein S6 in cells (Fig. 4G). Importantly, the
levels of palladin protein were significantly increased in the TSC1
mutant cells (Fig. 4G), supporting the conclusion that palladin
translation is regulated by the mTOR signaling cascade.
Palladin is a cytoskeletal regulator; however, its contribution
to neuronal morphogenesis is still unclear (Boukhelifa et al.,
2001; Shu et al., 2009). In temporal analyses of palladin in mouse
cortical neurons, palladin was expressed during early develop-
mental phases of neurons coinciding with axon extension (Fig.
4H). In immunocytochemical analyses in cortical neurons, pal-
ladin immunoreactivity was present in axon terminals and cell
bodies (Fig. 4I). In immunohistochemical analyses of the mouse
cerebral cortex, palladin-immunoreactivity was enriched in the
intermediate zone where axons extend from neurons in the cor-
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Figure 4. Palladin is translationally regulated by mTOR signaling and localized in axons. A, Lysates of cortical neurons treated with control vehicle (DMSO) or Torin 1 (100 nM) for 24 h were
immunoblottedwith thepalladin, phospho-S6, and S6 antibodies. Thepalladin intensitywas quantified andnormalizedby the loading control S6. The average relative abundance of three replicates
was indicated. B, Left, Lysates of cortical neurons transfected with control plasmid, palladin RNAi1, or palladin RNAi2 were immunoblotted with the palladin and ERK antibodies. The palladin
intensitywas quantified and normalized by the loading control ERK. The average relative abundance of three replicateswas indicated. Right, Lysates of HEK293T cells transfectedwith Flag-palladin
togetherwith control plasmid, palladin RNAi1, or palladin RNAi2were immunoblottedwith the Flag and ERK antibodies. The palladin intensitywas quantified and normalized by the loading control
ERK. The average relative abundance of three replicates was indicated. C, Lysates of cortical neurons treated with control vehicle (DMSO) or Torin 1 (100 nM) for 24 h were immunoblotted with the
Zfp36, phospho-S6, S6, and ERK antibodies. The Zfp36 intensity was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was indicated. D,
Lysates of cortical neurons treatedwith control vehicle (DMSO), Torin1 (100nM), Torin2 (100nM), or PP242 (2.5M) for 24hwere immunoblottedwith thepalladin, phospho-S6, andERKantibodies.
The palladin intensitywas quantified and normalized by the loading control ERK. The average relative abundance of three replicateswas indicated. E, Lysates of cortical neurons treatedwith control
vehicle (DMSO), Torin 1 (100 nM), or cytochalasin D (1M) for 2 h followed by 30 min treatment with puromycin were immunoblotted with the puromycin, phospho-S6, S6, and ERK antibodies.
Relative abundance of nascent proteins labeled with puromycin was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was indicated. F,
Lysates of cortical neurons treatedwith control vehicle (DMSO), Torin 1 (100 nM), or cytochalasin D (1M) for 24 hwere immunoblottedwith the palladin and ERK antibodies. The palladin intensity
was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was indicated. G, Lysates of TSC1 mutant Neuro2A cells or control cells were
immunoblotted with palladin, TSC1, phospho-S6, S6, and ERK antibodies. The schematic of mouse TSC1 gene indicates sites of mutations introduced with the CRISPR–Cas9 system. The palladin
intensity was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was indicated.H, Lysates of cortical neurons from different time points were
immunoblotted with the palladin and ERK antibodies. The palladin intensity was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was
indicated. I, Hippocampal neurons cultured for 5 d in vitrowere subjected to immunocytochemistrywith the palladin andIII Tubulin antibodies. Scale bar, 5m. J, Sections of E16mouse cerebral
cortex were subjected to immunohistochemistry with the palladin antibody (green), Tau-1 antibody (red) and stained with Hoechst (blue). Regions in the boxes 1–4 are enlarged in the bottom
panels. The palladin immunoreactivity is higher in the intermediate zonewhere axons reside comparedwith other parts of the cerebral cortex. Scale bar, 100m.K, Lysates ofwhole cells or isolated
neurites of cortical neurons treated with control vehicle (DMSO) or Torin 1 (100 nM) for 12 h were immunoblotted with the palladin, phospho-S6, S6, ERK, and nucleoporin antibodies. The palladin
intensity was quantified and normalized by the loading control ERK. The average relative abundance of three replicates was indicated in the graphs. Asterisks indicate p 0.05 in the graphs.
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tical plate (Fig. 4J). Thus, the temporal and spatial expression of
palladin suggest a function in axon morphogenesis.
To examine local synthesis of palladin in neurites, we isolated
neurites and treated them with Torin 1 (Fig. 4K). Neurons were
cultured on a filter bearing pores that accommodate neurites to
grow on the opposite side of their soma, and the neurites were
isolated by removing soma on the filter as described previously
(Vidaki et al., 2017).We found that Torin 1-treatment of isolated
neurites significantly reduced the protein level of palladin. Palla-
din protein level was similarly reduced by Torin 1-treatment in
the whole cells, suggesting that palladin is synthesized within
neurites as well as in the soma.
Palladin regulates axonal morphogenesis downstream of the
mTOR signaling pathway
Wenext askedwhether palladin plays a role in neuronalmorpho-
genesis downstreamofmTOR signaling. To assess the function of
palladin in neuronal morphogenesis, we first expressed palladin
in primary mouse hippocampal neurons. We found that signifi-
cantly higher percentage of palladin-expressing neurons pos-
sessed multiple axons compared with control neurons (Fig. 5A),
resembling the phenotype induced by activation of the mTOR
pathway (Li et al., 2008; Mejia et al., 2013). The exogenous
expression of palladin in axons was confirmed by immunocyto-
chemistry analysis with palladin antibody (Fig. 5B). The pheno-
type of multiple axons was consistently observed when palladin
was expressed as a GFP fusion protein (Fig. 5C).
Because our biochemical analyses suggest that palladin ex-
pression is regulated by mTOR activity, we next tested whether
palladin operates downstream of mTOR kinase by assessing the
percentage of cells withmultiple axons uponknockdownofTSC1
and knockdown of palladin simultaneously. As reported, sup-
pression of TSC1 induced formation of more than one axon per
neuron (Fig. 5D). Although knockdown of palladin did not
change the percentage of cells bearing multiple axons, palladin
knockdown reversed the multiple axon phenotype in TSC1
knockdown neurons (Fig. 5D). Immunocytochemistry analyses
revealed that palladin immunoreactivity signal was reduced upon
knockdown of palladin, validating the palladin antibody for im-
munocytochemistry (Fig. 5E). Knockdown of TSC1 upregulated
palladin immunoreactivity, while knockdown of palladin to-
gether with TSC1 knockdown reduced the palladin immunore-
activity (Fig. 5E), suggesting that palladin protein level is
controlled by the mTOR signaling pathway. These results dem-
onstrate that palladin regulates neuronal morphogenesis down-
stream of the mTOR signaling pathway.
Because SAD kinases are known to regulate axonmorphology
downstream of mTOR signaling pathway (Choi et al., 2008), we
also characterized the functional relationship between SAD ki-
nase and palladin in axon morphogenesis. The expression of
SAD-A kinase-induced supernumerary axons, and knockdown
of palladin failed to suppress the supernumerary axons induced
by SAD-A (Fig. 5F). These results suggest that SAD kinases op-
erate downstream of or in parallel with palladin in the control of
axon morphology induced by activation of mTOR signaling.
Collectively, we have found that mTOR signaling regulates
the translation of a specific set of proteins in neurons includ-
ing the cytoskeletal regulator palladin and thereby controls
axon morphogenesis.
Discussion
In this study, we have discovered that the mTOR signaling path-
way regulates the translation of specific proteins in neurons. We
have identified the cytoskeletal regulator palladin as a neuron-
specific translational target of mTOR signaling, which mediates
mTOR-regulation of axon morphogenesis. Ribosome profiling
analyses revealed that translation efficiency of palladin is modi-
fied upon acute inhibition of mTOR specifically in neurons,
while codon-specific ribosome occupancy and ribosomal stalling
were not altered significantly. Consistent with this finding, palla-
din protein amount was modulated by alterations of mTOR
activity. Palladin was localized in axons, and expression of
palladin-induced neurons to formmultiple axons. Supernumer-
ary axons induced by knockdown of the mTOR-regulator TSC1
were suppressed by simultaneous knockdown of palladin, sug-
gesting that palladin functions downstream of mTOR. Our find-
ings define a mechanism that regulates neuronal morphology via
mTOR-mediated control of protein translation.
ThemTOR signaling pathway controls diverse aspects of pro-
tein synthesis, including initiation and elongation of translation.
Consequently, we assessed changes of translation landscape upon
Torin 1 treatment frommultiple perspectives. We observed lim-
ited differences in codon-specific ribosome occupancy and trans-
lational pausing in cells upon exposure to the mTOR inhibitor
Torin 1. However, comparison of neurons and ES cells exposed
differential codon ribosome occupancy and ribosome pausing.
Recent studies suggest that the availability of aminoacyl-tRNA
varies in different cell types, leading to changes in codon optimal-
ity and codon ribosome occupancy at A-site (Plotkin and Kudla,
2011; Kirchner and Ignatova, 2015; Bazzini et al., 2016). Quanti-
tative understanding of the differences in codon optimality be-
tween neurons and ES cells might reveal the function and
importance of codon optimality during development and differ-
entiation. HowP-site codon ribosome occupancy is differentially
regulated in neurons and ES cells requires further study. Proline
codons were significantlymore occupied by ribosomes in ES cells
than in neurons, raising the possibility that eIF5A, a regulator of
proline elongation (Gutierrez et al., 2013; Schuller et al., 2017),
may be regulated in a cell-type-specific manner. Likewise, differ-
ences in ribosome stalling were more pronounced between neu-
rons and ES cells than between neurons treated with Torin 1 and
control neurons. It will be interesting to determine in future stud-
ies how ribosome stalling during translation elongation occurs
differentially in distinct cells.
Through the analysis of translation efficiency, we found that
mRNAs of 431 genes acutely responded to mTOR inhibition at
the level of translation specifically in neurons. Using GO term
enrichment analysis of the identified genes, we found that a sig-
nificant portion of the genes is associated with cytoskeletal regu-
lation, whereas energy and mitochondria-related genes were
enriched in the ES cell-specific mTOR-responsive genes. The dif-
ference in the function of the observed genes suggests that subsets
of genes are programmed to respond at the level of protein trans-
lation to adapt cells specifically to their differentiation status. It is
noteworthy that translation machinery proteins were commonly
downregulated by inhibition of mTOR, which may exhibit dif-
ferent effects in different cell types. It will be interesting to explore
how newly synthesized ribosomesmight regulate protein synthe-
sis in distinct cell types.
Palladin was enriched in axon terminals. Recent evidence
shows that protein synthesis occurs in axons, and local transla-
tion in axons enables neurons to control axon growth and regen-
eration (Jung et al., 2012; Korsak et al., 2016; Twiss et al., 2016;
Spaulding and Burgess, 2017).We observed that palladin protein
level in isolated neurites responded to Torin 1-treatment, sug-
gesting that palladin may be locally synthesized in axons. To un-
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Figure 5. Palladin controls axonal morphology downstream of mTOR signaling. A, Hippocampal neurons were transfected with the palladin expression plasmid or control plasmid together with a GFP
expressionplasmid2–6hafterplating.Fivedaysafter transfection,neuronsweresubjectedto immunocytochemistryusingtheGFP(green)andTau1(red)antibodies.Palladin-expressingneuronshadahigher
percentageofneuronsbearingmore thanoneaxon than control-transfectedneurons. Arrowheads andasterisks indicate axons and cell bodies, respectively.B, Hippocampal neuronswere transfectedwith the
palladin expression plasmid or control plasmid together with a GFP expression plasmid, and cultured for 3 d. The neurons were subjected to immunocytochemistry using the palladin (red) and GFP (green)
antibodies.Thepalladinintensitywassignificantlyincreasedbytheexogenousexpressionofpalladininaxons.Arrowheadsandasterisksindicateaxonsandcellbodies,respectively.C,Hippocampalneuronswere
transfectedwiththeGFP-fusedpalladinexpressionplasmidorcontrolGFPplasmid.Fivedaysaftertransfection,neuronsweresubjectedtoimmunocytochemistryusingtheGFP(green)andTau1(red)antibodies.
Palladin-GFP-expressing neurons had a higher percentage of neurons bearingmore than one axon than control-transfected neurons. Arrowheads and asterisks indicate axons and cell bodies, respectively.D,
Hippocampal neurons transfectedwith the TSC1 RNAi or control scrambled RNAi togetherwith the palladin RNAi 1, palladin RNAi 2, or the control plasmidwere analyzed. Palladin RNAi 1 and palladin RNAi 2
target distinct regions of palladin mRNA. The neurons were subjected to immunocytochemistry using the GFP (green) and Tau1 (red) antibodies. TSC1 RNAi increased the percentage of neurons
bearingmultiple axons comparedwith control-transfectedneurons,whereas palladinRNAi 1 or 2didnot alter thepercentageof neuronsbearingmultiple axons. Palladin knockdownwithbothRNAi
1 and 2 significantly reduced the percentage of neurons bearingmultiple axons in the background of TSC1 knockdown. E, Hippocampal neurons transfectedwith the TSC1 RNAi or control scrambled
plasmid together with the palladin RNAi 1, palladin RNAi 2 or control scrambled plasmid were analyzed by immunocytochemistry with palladin (red) and GFP (green) antibodies. F, Hippocampal
neurons transfected with the palladin RNAi 1 or control scrambled plasmid together with the SAD-A expression plasmid or control plasmid were analyzed. The neurons were subjected to
immunocytochemistry using the GFP (green) and Tau1 (red) antibodies. The SAD-A expression significantly induced supernumerary axons, and the palladin RNAi1 did not suppress the supernu-
merary axons induced by the SAD-A expression. Scale bars, 10m. Asterisks indicate p 0.05 in the all graphs.
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derstand the precise localization and dynamics of palladin
synthesis in axons, further detailed analyses of palladin synthesis
in axons are required. Neuronal compartment-specific ribosome
profiling might provide further insights into local regulation of
protein synthesis in neurons.
Although knockdown of palladin rescued the supernumerary
axons induced by knockdown of TSC1, knockdown of palladin
itself had little or no effect on the morphogenesis of axons (Fig.
5D). TSC1/2 overexpression has been reported to suppress axon
formation (Choi et al., 2008), suggesting that other proteins may
mediate the control of axonmorphogenesis upon inactivation of
mTOR signaling. Knockdown of palladin also failed to suppress
supernumerary axons induced by SAD-A expression, whereas it
suppressed supernumerary axons induced by knockdown of
TSC1. These results suggest that palladin operates downstreamof
TSC1, but upstream or in parallel with SAD kinases.
The identification of a function of palladin as a neuronalmor-
phogenesis effector protein ofmTOR signalingmay shed light on
pathogenesis of mTOR-related neurological disorders including
TSC. Among diverse clinical symptoms caused by TSC, neuro-
logical symptoms including intellectual disability, epilepsy, and
ASD may be caused through dysregulation of neuron-specific
mechanisms. Recent findings suggest that dysregulation of mTOR
signaling and protein synthesismight underlie broader neurological
disorders including autism and schizophrenia (Kelleher and Bear,
2008; Gururajan and van den Buuse, 2014).
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